Pulmonx Reports Third Quarter 2026 Financial Results

REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2026 ended September 30, 2026.

Recent Highlights * Achieved worldwide revenue of $22.8 million in the third quarter of 2026, a 6% increase over the same period last year on both a GAAP and constant currency basis * Delivered $14.9 million in U.S. revenue in the third quarter of 2026, representing a 7% year-over-year increase * Delivered $7.9 million in international revenue in the third quarter of 2026, representing a 5% year-over-year increase and an increase of 6% on a constant currency basis; excluding China, year-over-year international revenue increased 9% on both a GAAP and constant currency basis * Realized gross margin of 76% in the third quarter of 2026 * Demonstrated continued operating leverage from cost realignment efforts, reducing net loss by 40% and Adjusted EBITDA loss by 57% in the third quarter of 2026 as compared to the same period last year “We are very pleased to have returned to year-over-year revenue growth in the third quarter. We continue to execute on our commercial strategy, advance our clinical initiatives, and deliver the operating leverage we expected,” said Glen French, President and Chief Executive Officer of Pulmonx. “With a fully staffed U.S. sales leadership team, a more focused global commercial team, and a realigned cost structure, we are confident in our ability to build on this momentum and deliver growth while advancing our longer-term strategic priorities.”